Table 2 Costs for acute myocardial infarction, 2003–2007, Germany
From: Cost of clinical events in health economic evaluations in Germany: a systematic review
Study | Model type | Specification of disease severity | First cycle | Costs covered | Follow-up cycles | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time horizon | Unit cost (€) | Number of sourcesa | Direct costsb | Not specified | Time horizon | Unit cost (€) | Number of sourcesa | |||||
Hosp | Rehab | Other | ||||||||||
Year of costing: 2003 | ||||||||||||
Annemans L. Int J Clin Pract 2006; 60(9): 1129–37 [8] | Markov model | Fatal MI | Not specified | 2,880 | 1 | Yes | No follow-up costs considered | |||||
Lamotte M. Pharmacoeconomics 2006; 24(2): 155–69 [16] | Markov model | Fatal MI | Not specified | 2,880 | NA | Yes | No follow-up costs considered | |||||
Annemans L. Int J Clin Pract 2006; 60(9): 1129–37 [8] | Markov model | Non-fatal MI | Not specified | 3,123 | 1 | Yes | Annual follow-up costs | 1,907 | 1 | |||
Lamotte M. Pharmacoeconomics 2006; 24(2): 155–69 [16] | Markov model | Non-fatal MI | Not specified | 3,123 | NA | Yes | Annual follow-up costs | 1,907 | 1 | |||
Liebl A. Gesund ökon Qual Manag 2006; 11: 105–11 [18] | Decision tree | MI | Not specified | 5,878 | 1 | Yes | Follow-up: rehabilitation | 1,261 | > 1 | |||
Annual follow-up costs | 1,012 | > 1 | ||||||||||
Year of costing: 2004 | ||||||||||||
Lamotte M. Pharmacoeconomics 2006; 24(8): 783–95 [17] | Decision tree | Fatal MI | Acute period | 2,880 | 1 | Yes | No follow-up costs considered | |||||
Non-fatal MI | Acute period | 3,123 | 1 | Yes | No follow-up costs considered | |||||||
Gandjour A. Health Policy 2007; 83(2–3): 257–67 [14] | Markov model | MI | First 12 months | 4,618 | > 1 | Yes | Post-year 1 | 2,014 | > 1 | |||
Brüggenjürgen B. Eur J Health Econ 2007; 8(1): 51–7 [12] | Markov model | MI | First 12 months | 11,241 | 1 | Yes | Yes | Yes | Annual follow-up costs | 1,006 | 1 | |
Roze S. Curr Med Res Opin 2006; 22(7): 1415–24 [23] | Semi-Markov model | MI | Year of event | 15,011 | > 1 | Yes | Annual follow-up costs | 1,168 | 1 | |||
Year of costing: 2005 | ||||||||||||
Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 [25] | Semi-Markov model | Silent MI | Year of event | 0 | NA | Yes | No follow-up costs considered | |||||
Berg J. Clin Ther 2007; 29(6): 1184–202 [9] | Decision tree and Markov model | MI | Month 1 | 6,799 | > 1 | Yes | Months 2–12 | 5,129 | 1 | |||
Berger K. Curr Med Res Opin 2008; 24(1): 267–74 [11] | Markov model | MI | Initial treatment | 7,522 | 1 | Yes | First 6 months after event | 2,235 | 1 | |||
Second 6 months after event | 1,484 | 1 | ||||||||||
Subsequent 6- month intervals | 759 | 1 | ||||||||||
Scherbaum WA. Cost Eff Resour Alloc 2009; 7: 9 [25] | Semi-Markov model | Excluded silent MI | Year of event | 8,635 | 1 | Yes | Annual follow-up costs | 3,647 | 1 | |||
Weber CJ. Diabetes Sci Technol 2007; 1(5): 676–84 [28] | Markov model | MI | Year of event | 16,767 | 1 | Yes | Year after event | 1,253 | 1 | |||
Year of costing: 2006 | ||||||||||||
Valentine WJ. Adv Ther 2008; 25(6): 567–84 [27] | Semi-Markov model | MI | Year of event | 15,816 | > 1 | Yes | Annual follow-up costs | 1,230 | > 1 | |||
Schaufler TM. Gesund ökon Qual Manag 2009; 14: 71–5 [24] | Markov model | MI | First 12 months | 17,556 | 1 | Yes | Annual follow-up costs | 2,323 | 1 | |||
Berg J. Curr Med Res Opin 2008; 24(7): 2089–101 [10] | Decision tree and Markov model | MI | Month 1 | 6,899 | > 1 | Yes | Months 2–12 | 5,204 | 1 | |||
Annual follow-up costs | 2,035 | 1 | ||||||||||
Year of costing: 2007 | ||||||||||||
Mittendorf T. Diabetes Obes Metab 2009; 11(11): 1068–79 [19] | Semi-Markov model | MI | Year of event | 8,614 | 1 | Yes | Annual follow-up costs | 1,292 | NA | |||
Schwander B. Value Health 2009; 12(6): 857–71 [26] | Markov model | MI | First 12 months | 11,683 | > 1 | Yes | Annual follow-up costs | 2,803 | > 1 | |||